Skip to content

US · BRKRP · MEDICAL - SPECIALTIES

Bruker Corporation (BRKRP) intrinsic value and stock valuation

$411.77as of 2026-11-21 · Mkt cap 7.99B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Bruker Corporation DCF and intrinsic value

InvestorsCraft values BRKRP with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from BRKRP’s statements →

Bruker Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Specialties Billerica, MA 01821 bruker.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$3.44B+11.6% 5y CAGRd
20112025
Net income
-$-8.6M
20112025
Free cash flow
$13.9M-43.2% 5y CAGRd
20112025
Total equity
$2.51B+20.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$3.44B$3.37B$2.96B$2.53B$2.42B
Operating income$236M$253.1M$436.9M$432.7M$413.3M
Net income-$-8.6M$113.1M$427.2M$296.6M$277.1M
EPSd-$-56.65K$756.5K$2.9M$1.99M$1.81M
Operating cash flow$134.1M$251.3M$350.1M$274.4M$282.4M
Capital expenditure-$-120.2M-$-115.3M-$-106.9M-$-129.2M-$-92M
Free cash flow$13.9M$136M$243.2M$145.2M$190.4M
Total assets$6.24B$5.81B$4.25B$3.61B$3.65B
Total debt$2.04B$2.25B$1.38B$1.27B$1.39B
Net debt$1.74B$2.06B$891.3M$624.9M$325.7M
Total equity$2.51B$1.82B$1.41B$1.13B$1.08B
Cash and short-term investments$298.8M$183.4M$488.3M$645.5M$1.17B
Income statement
20252024202320222021
Revenue$3.44B$3.37B$2.96B$2.53B$2.42B
Cost of revenue$1.86B$1.72B$1.45B$1.23B$1.21B
Gross profit$1.58B$1.65B$1.51B$1.31B$1.21B
Research and development expenses$395.2M$376.5M$294.8M$235.9M$220.8M
Selling, general and administrative expenses$946.5M$893.8M$729.4M$607.4M$562.3M
Other expenses$0.00$126.1M$52.2M$29.7M$13.2M
Operating expenses$1.34B$1.4B$1.08B$873M$796.3M
Cost and expenses$3.2B$3.11B$2.53B$2.1B$2B
Interest income$14.8M$9.3M$7.5M$2.8M$900K
Interest expense$60.3M$47.9M$16.4M$16.1M$14.3M
Depreciation and amortization$220.3M$183.8M$114.9M$88.7M$89.2M
Ebitda$302.6M$438.6M$675.5M$518.7M$497.1M
Operating income$236M$253.1M$436.9M$432.7M$413.3M
Total other income/expenses, net-$-215M-$-47.9M$109.3M-$-17.8M-$-19.7M
Income before tax$21M$205.2M$546.2M$414.9M$393.6M
Income tax expense$29.3M$91.4M$117.7M$116.4M$113M
Net income-$-8.6M$113.1M$427.2M$296.6M$277.1M
Weighted average shares outstanding$151.8M$149M$146.4M$148.6M$151.4M
Weighted average diluted shares outstanding$151.8M$149.5M$147.2M$149.4M$152.9M
Balance sheet
20252024202320222021
Cash and short-term investments$298.8M$183.4M$488.3M$645.5M$1.17B
Net receivables$736M$701.2M$621.8M$595.3M$416.9M
Inventory$1.09B$1.07B$968.3M$800.1M$710.1M
Total current assets$2.21B$2.05B$2.16B$2.11B$2.47B
Property, plant and equipment, net$910.6M$814.8M$691.4M$538.2M$466M
Goodwill and intangible assets$2.45B$2.42B$913.1M$728.5M$551.3M
Long-term investments$8.2M$0.00$0.00$0.00$0.00
Total non-current assets$4.03B$3.75B$2.09B$1.5B$1.18B
Total assets$6.24B$5.81B$4.25B$3.61B$3.65B
Accounts payable$215.9M$234.1M$202.7M$178.4M$147.4M
Short-term debt$51.8M$64.6M$144.5M$35.1M$130.3M
Deferred revenue$441.3M$438.2M$400M$370.2M$335.9M
Total current liabilities$1.28B$1.28B$1.2B$914.3M$938.5M
Long-term debt$1.99B$2.18B$1.24B$1.24B$1.26B
Deferred revenue, non-current$109.1M$100M$91.5M$101.6M$50.2M
Total non-current liabilities$2.45B$2.71B$1.63B$1.57B$1.63B
Capital lease obligations$296.6M$151M$98.1M$51.2M$59.7M
Total liabilities$3.73B$3.99B$2.84B$2.48B$2.57B
Common stock$1.8M$1.8M$1.7M$1.7M$1.7M
Retained earnings$2.36B$2.41B$2.32B$1.93B$1.66B
Accumulated other comprehensive income (loss)-$-79.5M-$-103.5M$6M$14.8M-$-8.2M
Total equity$2.51B$1.82B$1.41B$1.13B$1.08B
Total investments$8.2M$0.00$0.00$0.00$100M
Total debt$2.04B$2.25B$1.38B$1.27B$1.39B
Net debt$1.74B$2.06B$891.3M$624.9M$325.7M
Cash flow statement
20252024202320222021
Net income$29.2M$113.8M$427.2M$298.5M$280.6M
Depreciation and amortization$220.3M$183.8M$114.9M$88.7M$89.1M
Stock-based compensation$0.00$25.3M$24M$27.7M$17.2M
Change in working capital-$-144.6M-$-78.2M-$-87.8M-$-144.1M-$-125.2M
Accounts receivable$0.00-$-40.6M-$-900K-$-67.9M-$-95.3M
Inventory$0.00-$-69.8M-$-125M-$-137.9M-$-67M
Accounts payable-$-86M$20.8M$23.1M$33.3M$61.8M
Net cash provided by operating activities$134.1M$251.3M$350.1M$274.4M$282.4M
Investments in property, plant and equipment-$-90.8M-$-115.3M-$-106.9M-$-129.2M-$-92M
Acquisitions, net-$-73.9M-$-1.6B-$-226.6M-$-182.3M-$-65M
Net cash used for investing activities-$-196.5M-$-1.76B-$-326M-$-251.6M-$-192.4M
Common stock issued$669.7M$403M$9.5M$2.8M$7M
Common stock repurchased-$-10M$0.00-$-152.3M-$-263.1M-$-153.3M
Dividends paid-$-22.8M-$-30.2M-$-29.4M-$-29.8M-$-24.2M
Net cash used for financing activities$135.1M$1.23B-$-193.4M-$-415.3M$318.7M
Net change in cash$116.4M-$-304.9M-$-157.1M-$-423M$386.2M
Cash at end of period$303.1M$186.7M$491.6M$648.7M$1.07B
Operating cash flow$134.1M$251.3M$350.1M$274.4M$282.4M
Capital expenditure-$-120.2M-$-115.3M-$-106.9M-$-129.2M-$-92M
Free cash flow$13.9M$136M$243.2M$145.2M$190.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Bruker Corporation

        Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

        CEO
        Frank H. Laukien
        Employees
        11.09K
        Beta
        1.39

        Explore

        Frequently asked questions

        What is the intrinsic value of Bruker Corporation (BRKRP)?

        Bruker Corporation (BRKRP) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BRKRP undervalued?

        BRKRP trades at a price of $411.77 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.